Faculty

Program Description
According to the American Association of Clinical Endocrinologists (AACE), more than 60% of diabetes mellitus (DM) patients do not reach HbA1c target goals. Advances in the understanding of glucose homeostasis have helped identify new therapeutic targets, such as incretin hormones, which may address some of the unmet needs of conventional type 2 diabetes medications. These agents are associated with a low risk of unwanted adverse events and offer physicians additional options to deliver individualized care.

DM management recommendations are being updated regularly, and guidelines are a helpful starting point for physicians, providing them with evidence-based treatment options. However, treatments should be individualized to each patient, and DOs need all the latest information and up-to-date data in order to deliver such individualized care.

Education can bridge the gap between physicians’ current understanding of the role of treatment guidelines and incretin therapies in type 2 diabetes management, and the confident application of that knowledge in clinical practice.

Target Audience
This activity is intended for osteopathic physicians.

Learning Objectives

This program is designed to address the following IOM competencies: provide patient centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate improved ability to:

• Diagnose a patient with DM based on the new ADA diagnostic criteria.
• Make patient-oriented therapeutic decisions based on the safety and efficacy of the treatment regimen, as well as a patient’s presentation, preference, and risks for hypoglycemia and cardiovascular events.
• Explain the MOA of incretin therapies and discuss how each agent fits into the present armamentarium for T2DM.
• Explain how future formulations might help address the remaining clinical gaps in T2DM management.

Conflict of Interest Policy
The American Osteopathic Association and Rockpointe Corporation adhere to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of a continuing medical education program are required to disclose any relevant financial relationships with any commercial interest to AOA or Rockpointe, as well as to learners. All conflicts are identified and resolved by AOA and Rockpointe in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Natasha N. Bray, DO: Nothing to Disclose

Ellen Miller, MD: Speaker: Boehringer Ingelheim, Lilly, Merck, Amgen

Kelly Anne Spratt, DO: Advisory Board: Digitas Health (Medical Information Company)

Planner and Manager Disclosures

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Carole Drexel, PhD; Bradley Pine; Blair St. Amand; Jay Katz; Gregg Lapin: Nothing to Disclose

Accreditation Statement
The AOA’s continuing medical education program (CME) strives for growth of knowledge, refinement of skills, and the deepening of understanding for the osteopathic profession. The AOA Board of Trustees establishes accreditation policy for osteopathic CME sponsors. The Council on Continuing Medical Education (CCME) has been delegated authority by the AOA Board of Trustees to monitor osteopathic CME and to grant or deny Category 1 accreditation status to osteopathic CME sponsors.

Designation Statement
The American Osteopathic Association’s Council on Continuing Medical Education approved the activity for 1.0 hour of Category 1-B AOA credit.

Statement of Commercial Support
This program is supported through an educational grant from Amylin Pharmaceuticals, Inc. and Lilly USA, LLC.

FDA Disclosure
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements
In order to view this monograph, your computer must have Adobe Reader to view PDF files. Adobe Reader can be downloaded for free here.

Instructions for Participants and Obtaining CME Credit
There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.0 hour. To receive and print their certificates, participants must demonstrate mastery of the presented material via the post-test.

All questions about this activity should be addressed to: contact@potomacme.org.

Jointly Sponsored by the American Osteopathic Association and Rockpointe Corporation